Literature DB >> 16495033

Enantiomeric resolution of doxazosin mesylate and its process-related substances on polysaccharide chiral stationary phases.

R Nageswara Rao1, D Nagaraju, A Narasa Raju.   

Abstract

High-performance liquid chromatographic methods for separation of racemic doxazosin mesylate and its synthetic precursors on polysaccharide based stationary phases viz., amylose tris-(3,5-dimethylphenylcarbamate) (Chiralpak AD-H) and cellulose tris-(3,5-dimethylphenylcarbamate) (Chiralcel OD-H) were developed. The base line separation with Rs>1.50 was obtained using a mobile phase containing n-hexane-alcohol-0.1% diethylamine (ethanol, 1-propanol and 2-propanol) in various proportions. The effect of concentration of the alcoholic modifiers on the resolution was studied. A good separation was achieved on amylose based Chiralpak AD-H column when compared with cellulose based Chiralcel OD-H. The effects of structural features of the solutes and solvents on discrimination between the enantiomers were examined. The detection was carried out at 240 nm with UV detector while identification by polarimetric detector connected in series. The method was suitable not only for process development of doxazosin mesylate but also determination of enantiomeric purity of bulk drugs and pharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495033     DOI: 10.1016/j.jpba.2006.01.019

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Rapid and sensitive online determination of some selective α1-blockers by flow injection analysis with micelle-enhanced fluorescence detection.

Authors:  Niveen A Mohamed; Sameh Ahmed; Sally A El Zohny
Journal:  J Fluoresc       Date:  2013-07-20       Impact factor: 2.217

2.  Determination of Alkyl Methanesulfonates in Doxazosin Mesylate by Gas Chromatography-mass Spectrometer.

Authors:  C Sitaram; R B Rupakula; B N Reddy; C S P Sastry
Journal:  Indian J Pharm Sci       Date:  2011-01       Impact factor: 0.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.